Macroscale mesenchymal condensation to study cytokine-driven cellular and matrix-related changes during cartilage degradation by Weber, Marie-Christin et al.
Biofabrication
     
PAPER • OPEN ACCESS
Macroscale mesenchymal condensation to study
cytokine-driven cellular and matrix-related
changes during cartilage degradation
To cite this article: Marie-Christin Weber et al 2020 Biofabrication 12 045016
 
View the article online for updates and enhancements.
Recent citations
Functional ScaffoldFree Bone Equivalents
Induce Osteogenic and Angiogenic
Processes in a Human In Vitro Fracture
Hematoma Model
Moritz Pfeiffenberger et al
-
A Human Osteochondral Tissue Model
Mimicking Cytokine-Induced Key Features
of Arthritis In Vitro
Alexandra Damerau et al
-
Glucocorticoids: surprising new findings on
their mechanisms of actions
Frank Buttgereit
-
This content was downloaded from IP address 129.177.146.152 on 26/05/2021 at 12:09












this work may be used




of this work must
maintain attribution to
the author(s) and the title
of the work, journal
citation and DOI.
PAPER
Macroscale mesenchymal condensation to study cytokine-driven
cellular and matrix-related changes during cartilage degradation
Marie-Christin Weber1,9, Lisa Fischer2,9, Alexandra Damerau1,3, Igor Ponomarev4, Moritz Pfeiffenberger1,3,
Timo Gaber1,3,5, Sebastian Götschel2, Jens Lang6, Susanna Röblitz7, Frank Buttgereit1,3,5, Rainald Ehrig2,8
and Annemarie Lang1,3,5,10
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Institute of Health, Julius Wolff Institute, Berlin, Germany
9 These authors contributed equally.
10 Author to whom any correspondence should be addressed.
E-mail: annemarie.lang@charite.de
Keywords: in vitromodel, tissue engineered cartilage, cytokine-induced inflammation, in silicomodel
Supplementary material for this article is available online
Abstract
Understanding the pathophysiological processes of cartilage degradation requires adequate model
systems to develop therapeutic strategies towards osteoarthritis (OA). Although different in vitro or
in vivomodels have been described, further comprehensive approaches are needed to study specific
disease aspects. This study aimed to combine in vitro and in silicomodeling based on a
tissue-engineering approach using mesenchymal condensation to mimic cytokine-induced cellular
and matrix-related changes during cartilage degradation. Thus, scaffold-free cartilage-like
constructs (SFCCs) were produced based on self-organization of mesenchymal stromal cells
(mesenchymal condensation) and (i) characterized regarding their cellular and matrix composition
or secondly (ii) treated with interleukin-1β (IL–1β) and tumor necrosis factor α (TNFα) for
3 weeks to simulate OA-related matrix degradation. In addition, an existing mathematical model
based on partial differential equations was optimized and transferred to the underlying settings to
simulate the distribution of IL–1β, type II collagen degradation and cell number reduction. By
combining in vitro and in silicomethods, we aimed to develop a valid, efficient alternative
approach to examine and predict disease progression and effects of new therapeutics.
1. Introduction
Cartilage is a highly complex tissue that can be
found in different forms at various locations in
the body. The cartilage type is determined by the
cell density and the composition of the extracel-
lular matrix (ECM) resulting in function-adapted
properties. Fibrous cartilage found in the menisci or
intervertebral discs is cell-poor and rich of type I col-
lagen, while elastic cartilage has a high cell density
and elastic fibers. Articular cartilage, a subtype of
hyaline cartilage, is organized in a unique structure
consisting of different layers and distinct chondrocyte
phenotypes enabling impact absorbance and pressure
distribution within joints. The ECM of articular car-
tilage is defined by high concentrations of type II col-
lagen and several proteoglycans, mainly aggrecan and
glycosaminoglycans binding water within the tissue.
Cartilage in general evolves during embryonic devel-
opment through mesenchymal condensation [1].
Cartilage degradation within articular joints is
a major feature of osteoarthritis (OA). OA ranks
© 2020 The Author(s). Published by IOP Publishing Ltd
Biofabrication 12 (2020) 045016 M-CWeber et al
among the most common musculoskeletal disorders
with no available cure except for joint replacement
surgery. The progression of cartilage degradation is
driven by an imbalance in anabolic and catabolic
metabolic processes that normally ensure cartilage
maintenance and homeostasis [2]. The inflammat-
ory microenvironment results in increased expres-
sion of specialized matrix-degrading enzymes such
as matrix-metalloproteinases (MMP) or a disin-
tegrin and metalloproteinase with thrombospondin
motifs (ADAMTS). MMPs, calcium-dependent zinc-
containing endopeptidases, are involved in different
physiological and pathological remodeling processes.
MMP–1, MMP–3, MMP–8 and MMP–13 have been
found to be increased in osteoarthritic cartilage and
to be responsible for specifically degrading collagen
fibers, but also proteoglycans [3].
The pathogenesis of OA has not been fully
understood so far, partly due to the lack of an
optimal model system which sufficiently incorpor-
ates all aspects of the disease [2, 4]. A vast variety of
in vivo, ex vivo, in vitro and (to some extent) in silico
models for OA already exists, and they all mimic
distinct features of OA pathophysiology including
the degradation of ECM, inflammation and altera-
tions in cell metabolism, viability and differentiation
[5–7]. In vivo OA models are crucial for transla-
tional research, butmainlymake use of small rodents,
especially mice, although these species show signific-
ant differences in articular cartilage anatomy, load-
ing conditions and life span [8, 9]. Thus, in vitro
models represent an important tool to investigate the
mechanisms involved in the pathogenesis of OA and
to examine possible therapeutic options. Model sys-
tems include monolayer cultures with cell lines or
primary chondrocytes, co-cultures, 3D-cultures, car-
tilage explants from either humans or animals or
even new cartilage-on-a-chip approaches [10]. How-
ever, a major challenge is the source of primary
chondrocytes or explants, since healthy human car-
tilage samples are rare. Thus, sample collection is
mainly undertaken from joint replacement surger-
ies. Independent of the cell source, it is a con-
sensus that the 3D cultivation of primary chondro-
cytes resembles the in vivo situationmore closely [11].
However, most 3D culture systems involve a scaffold
to provide the cells with a predetermined structure,
although their distinct effects on the cells are often
not considered. Recent developments aim to establish
scaffold-free tissue engineered cartilage which could
serve as a promising approach for cartilage repair
in vivo, but also as an excellent in vitro model, since
ECM formation and degradation can be evaluated
without the interference of a scaffold [12–14]. The
increasing understanding on developmental biology
resulted in improved tissue-engineering approaches
using e.g. self-assembly and self-organization [12]
processes that recapitulate mesenchymal condens-
ation and chondrogenesis [13, 15–18]. Therefore,
mainly mesenchymal stromal cells (MSCs) are used
for scaffold-free cartilage tissue engineering owing
to their benefits in terms of availability, proliferat-
ive capacity and phenotype stability when compared
to primary chondrocytes. Several groups have proven
the possibility to produce in vitro cartilage grown
scaffold-free based on MSCs [13, 15]. The main aim
is to develop cartilage transplants as a therapeutic
option to repair cartilage defects in joints such as the
knee or ankle [15]. However, it has been also pro-
posed that those scaffold-free cartilage analogous can
be also used for experimental studies [13].
In addition to biological models, in silico model-
ing offers a powerful tool to bring clarity to the pro-
cesses that evolve during in vitro or in vivo model-
ing [19, 20]. Few studies have been performed so far
to obtain parameters for in silicomodeling, although
a combination of biological data with mathematical
modeling promises to accelerate translation in OA
research [21–23]. Catt et al describe a partial differen-
tial equation (PDE)model of cartilage with a focus on
the production of ECM and the growth of chondro-
cytes synergistically leading to tissue expansion [22].
Moreover, Kar et al investigated cartilage degrada-
tion induced by interleukin-1β (IL–1β) using a PDE
model based on data from the literature together with
existing experimental data to calibrate their model
[23]. In contrast, Baker et al used an ordinary differ-
ential equation (ODE) system to describe the interac-
tion of anti-inflammatory cytokines, proteinases and
fibronectin in osteoarthritic cartilage [24]. Since bio-
mechanical influences are of utmost interest, several
approaches have already been used, and these include
modelling arthritic cartilage under cyclic compress-
ive loading or a combining of inflammation and bio-
mechanics [25, 26].
In this study, we tested whether scaffold-free
cartilage-like constructs (SFCCs), engineered bymac-
roscale mesenchymal condensation and biomechan-
ical stimulation, can be used as an in vitro model
to investigate cytokine-driven cellular and matrix-
related changes during cartilage degradation that
occur e.g. during OA. In addition, we evaluated the
feasibility to adapt an existing OA-related mathemat-
ical model to resemble the matrix degradation pro-
cesses in these SFCCs (figure 1).
2. Material andmethods
2.1. hMSC isolation and expansion
Human mesenchymal stromal cells (hMSCs) were
obtained from human femoral bone marrow of
patients undergoing hip arthroplasty (provided by
the Centre for Musculoskeletal Surgery, Charité—
Universitätsmedizin Berlin and distributed by the
‘Tissue Harvesting’ Core Facility of the Berlin Insti-
tute of Health Center for Regenerative Therapies
(BCRT), Germany). All protocols were approved by
the Charité—Universitätsmedizin Ethics Committee
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Figure 1. Overview on our current approach and study design.
and performed according to the Helsinki Declara-
tion (ethical approval EA1/012/13). Donor informa-
tion is summarized in table 1. hMSCs were cultivated
in DMEM GlutaMAX™ Medium (Thermo Fisher
Scientific, MA) with 20% StemMACS™ (Miltenyi
Biotech, Germany), 10% fetal calf serum (FCS)
(Thermo Fisher Scientific,MA), 100 unitsml−1 peni-
cillin and 0.1 mg ml−1 streptomycin (Thermo Fisher
Scientific, MA) at a temperature of 37 ◦C in 5% CO2
atmosphere. hMSCs were cultured separately for each
donor and characterized by flow cytometry (CD90+,
CD105+, CD73+, CD14−, CD20−, CD34−, CD45−,
HLA-DR−) as well as osteogenic, adipogenic and
chondrogenic differentiation assays. Only cells suc-
cessfully passing the characterization were further
cultivated up to passages 3–5.
2.2. Generation of SFCCs and experimental setup
SFCCs were produced based on a patented protocol
(patent no.: EP1550716B1) [27]. In short, around
10–15 million hMSCs from one donor (randomized)
were transferred into a 3D state via centrifugation
followed by maturation for 3 to 4 weeks applying
biomechanical forces until reaching cartilage-like
stiffness [28]. Due to the input of biomechanical
forces, the SFCCs are formed by self-organization
[12]. Before the experiments, SFCCs were cultured
for 4 weeks in DMEM GlutaMAX™ Medium, sup-
plemented with 10% FCS, 100 units ml−1 penicillin,
0.1 mg ml−1 streptomycin (all from Thermo Fisher
Scientific,MA) and 9.39mg l−1 ascorbic acid (Sigma-
Aldrich, MO); in the following, this is referred to as
‘standard medium’. In a first step, SFCCs were cul-
tivated under cytokine-free conditions and samples
were taken on days 0, 7, 14 and 21 (n = 3 per
time point). Secondly, to resemble the proinflammat-
ory state that has been described in patients with
early OA, stimulation was performed using standard
medium supplemented with 50 ngml−1 recombinant
human IL–1β (2 × 108 IU mg−1) and 100 ng ml−1
recombinant human tumor necrosis factor alpha
(TNFα) (2 × 107 IU mg−1; both from Immun-
oTools, Germany). Samples of cytokine stimulated
SFCCs (STIM) and controls (CTL) were taken on day
3
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Table 1. hMSC donor information and related experiments.
Patient Age Sex Characterization Type of experiment
1 71 Female + Experiments under non-inflammatory conditions Histology RNA analysis
2 56 Female +
3 85 Female +
4 59 Female + Experiments under non-inflammatory and inflammatory conditions
5 79 Male + Histology RNA analysis
6 66 Male +
21 (n = 9 with triplicates of 3 different donors). A
subset of cytokine stimulated SFCCs was further cul-
tivated for 21 more days under cytokine free con-
ditions to evaluate whether regeneration is possible
(REG) (n = 9 with triplicates of 3 different donors).
SFCCs fromeach donorwere randomized into groups
and analysis was performed in a blinded fashion by
numbering samples at random.
2.3. Histological staining and immunofluorescence
Samples for histological analysis were first fixed in
4%paraformaldehyde (PFA) for 6 h and subsequently
treated with 10%, 20% and then 30% sucrose solu-
tion, each for 24 h. After fixation, samples were
cryo-embedded in SCEM embedding medium and
cryo-sections of 8-µm thickness were prepared using
cryofilms (Sectionlab, Japan). Prior to each histolo-
gical and immunohistochemical staining procedure,
slices were dried for 20min at room temperature. Von
Kossa and Alizarin red staining were performed as
published previously [29].
2.4. H&E and Alcian blue staining
Hematoxylin and eosin (H&E) staining was per-
formed according to the following protocol: fixation
with 4% PFA (10 min), washing with distilled water
(5 min), first staining step in Harris’s hematoxylin
solution (7 min) (Merck, Germany), washing with
distilled water (2×), differentiation step in 0.25 ml of
concentrated HCl in 100 ml of 70% ethanol, wash-
ing with tap water (2× 10 min), second staining step
in 0.2% eosin (2 min) (Chroma Waldeck, Germany),
differentiation in 96% ethanol, washing in 96% eth-
anol, 100% ethanol (2× 2min), fixation with xylol (2
× 2 min), covering of stained slices with Vitro-Clud®
(R Langenbrinck GmbH, Germany).
Alcian blue staining was performed according
to the following protocol: fixation with 4% PFA
(10 min), washing with distilled water (5 min), 3%
acetic acid (3 min), first staining step in 1% Alcian
blue 8GX (Sigma-Aldrich, MO) in 3% acetic acid, pH
2.5 (30 min), washing in 3% acetic acid, washing in
distilled water, second staining step in Nuclear fast
red-aluminum sulfate solution (Chroma Waldeck,
Germany), washing in distilled water, graded ethanol
series (80%, 96%, 100%) (2 min each), fixation with
xylol (2× 2min), covering of stained sliceswithVitro-
Clud® (R. Langenbrinck GmbH, Germany)..
2.5. Immunohistochemistry
Immunohistochemistry was performed according to
the following protocol: rehydration with phosphate
buffered saline (PBS) (10 min), blocking with 3%
H2O2 (30 min), washing with PBS (5 min), block-
ing with 5% normal horse serum (Vector Laborat-
ories, CA) in 2% bovine serum albumin (BSA)/PBS,
overnight incubation with primary antibody for type
I collagen and type II collagen at 4 ◦C (ab6308, 1:500,
Abcam, UK and Ms 6B3, 1:10, quartett Immunodia-
gnostika, Germany), washing in PBS (2× 5 min),
incubationwith 2% secondary antibody (biotinylated
horse anti-mouse IgG antibody, Vector Laboratories,
CA) diluted in 2× normal horse serum/2% BSA/PBS
(30 min), washing in PBS (2× 5 min), incubation
with avidin-biotin complex (VECTASTAIN® Elite®
ABC HRP Kit, Vector Laboratories, CA) (50 min),
washing with PBS (2× 5 min), incubation with
DAB under microscopic control with time measure-
ment (DAB peroxidase (HRP) Substrate Kit, Vector
Laboratories, CA), stopping with PBS (2×), washing
in distilled water, counterstaining in Mayer’s hem-
atoxylin 1:2 (Sigma-Aldrich, MO), blueing in tap
water (5 min), washing in distilled water, covering of
stained slices with Aquatex® (Merck, Germany). Pic-
tures were taken with the Axioskop 40 optical micro-




Immunofluorescence staining was used to quantify
MMPs. First, the slides were air-dried at room tem-
perature and then rehydrated with PBS for 10 min.
Subsequently, unspecific binding sites were blocked
with PBS/5%FCS for 30min. PrimaryMMP–13 anti-
body (mouse anti-human; Invitrogen Thermo Fisher
Scientific, monoclonal, MA5-14247) was diluted
1:200 in PBS/5% FCS/0.1% Tween® 20 and primary
MMP–1 antibody (mouse anti-human; Invitrogen
Thermo Fisher Scientific, monoclonal, MA5-15872)
was diluted 1:500 in PBS/5% FCS/0.1% Tween®
20 and incubated according to the manufacturer’s
instruction for 3 h. After each incubation step, the
preparation was washed 3 times with PBS/0.1%
Tween® 20. The secondary antibody (goat anti-
mouse A546; Invitrogen Thermo Fisher Scientific,
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A-11003) was diluted 1:500 in PBS/5% FCS/0.1%
Tween® 20 and applied for 2 h. In the final stain-
ing step, core staining was performed using DAPI
(1 µg ml−1 diluted in PBS/5% FCS/0.1% Tween®
20) for 15 min. After air bubble-free covering with
FluoroMount covering medium, microscopic evalu-
ation was performed with the fluorescence micro-
scope BZ-9000A (Keyence, Germany) using the DAPI
and TRITC channels. Image analysis was performed
using ImageJ. In order to determine the cell number,
the Find Maxima tool was used for the DAPI image,
whereas the area of MMP positive signals was meas-
ured using the Color Threshold tool. TUNEL stain-
ing (Sigma Aldrich, USA) was performed according
to the manufacturer’s instructions. The positive con-
trol was treated with desoxyribonuclease (DNase) I
(0.34 Kunitz units, Qiagen Germany) for 10 min.
2.7. Histomorphometry
Histomorphometry was performed using FIJI ImageJ
1.52i [30, 31]. H&E stained sections were used to
analyze the cell count per area and cell distribution
within the SFCCs. The cell count per tissue area
(cells mm−2) was identified from H&E overview pic-
tures of each SFCC with 50× magnification using a
modified color deconvolutionmethod [32] (for addi-
tional detail information see figure A1 and table A1).
First, a free hand selection tool was used to define
the region of interest (ROI) for the section outline
representing the Total Area (Tt.A.) of the section.
The Gap Area (Gp.A.) where no tissue was present
was identified using the Color Threshold tool and
subtracted from the Tt.A. to obtain the Total Tissue
Area (Tt.T.A.). Next, the Color Deconvolution plu-
gin of ImageJ with a vector to separate hematoxylin
and eosin staining into each color layer was applied.
Within the hematoxylin layer, the cell nuclei were
identified by applying the Threshold tool of ImageJ
based on their brightness within the layer. A binary
image was created representing the nuclei of the cells
within the section. Finally, cell count was performed
from these binary images with a combination of the
Particle Analysis tool in ImageJ andmanual counting.
The cell count for the Tt.T.A. was performed
identically for the experiments under normal and
inflammatory conditions. A ROI for the Outer Area
(Ot.A.) was identified with a manual selection tool
for the experiment under normal conditions. For the
stimulation experiment, ROIs were determined for
the Ot.A. with a reduction of section diameter to 0.95
for X- and Y-axes, which then was further divided
into an Outer Core Area (Ot.C.A.) and Inner Core
Area (In.C.A.) by another reduction of the diameter
by 0.5 for X- and Y-axes. Sections of 2 different
levels per SFCC were analyzed respectively and the
mean taken for statistical analysis. In order to ana-
lyze the immunohistochemically stained sections, the
DAB coverage area was measured for type I collagen
(Col–1) and type II collagen (Col–2), respectively.
Two to three pictures of 100× magnification per
section were analyzed and the mean taken for statist-
ical analysis. Tt.T.A was determined again by measur-
ing the Tt.A. and subtracting Gp.A. which was identi-
fiedwith the Color Threshold tool in ImageJ. The area
stained positive for Col–1 and Col–2 was defined by
the Color Threshold tool also. Color Thresholds were
determined for each set of staining separately.
2.8. RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated from the SFCCs using the
TissueRuptor II (QIAGEN, Germany) to homogen-
ize the tissue and the RNeasy Fibrous Tissue Mini
Kit (QIAGEN, Germany) was used to extract the
RNA according to the provided protocols. RNA con-
centrations were measured via NanoDrop Fluoro-
meter (Thermo Fisher Scientific, MA) and RNA
integrity was confirmed via the 2100 Bioanalyzer
(Agilent Technologies, CA). Sensiscript RT Kit (QIA-
GEN, Germany) was used for cDNA synthesis with
50 ng per reaction according to the manufactur-
ers’ instructions. Primers were designed using Primer
Blast (NCBI, MD) and sequence analysis of qPCR
products was performed at LGC genomics (LGS gen-
omics GmbH, Berlin, Germany) to confirm primer
specify (for primer sequences see table 2). To ana-
lyze RNA expression, quantitative PCR (qPCR) was
performed using the DyNAmo ColorFlash SYBR
Green qPCR kit (Thermo Fisher Scientific, MA) at a
Mx3000P qPCR System (Agilent Technologies, CA)
with approximately 1.5 ng cDNA per 20 µl reaction
and the following temperature profile: 7 min denat-
uration at 95 ◦C, 45 cycles of 5 s at 95 ◦C, 7 s at
57 ◦C and 9 s at 72 ◦C. Two technical replicas per
sample and gene were performed. After each qPCR
run, a melting curve analysis was performed to con-
firm primer specificity. In cases where no amplific-
ation curve reached the threshold before 45 cycles,
the threshold-cycle value (Ct-value) was assumed to
be 45. Gene expression data is shown as ∆Ct-value
(=2−∆Ct) with normalization to the housekeeping
gene elongation factor 1-alpha (EF1A).
2.9. RNA isolation from human cartilage
Human cartilage was collected from femoral con-
dyles taken during total knee replacement surgeries
(ethical approval EA1/012/13). Cartilage was harves-
ted from areas as unaffected as possible and trans-
ferred to RNAlater (QIAGEN, Germany) for 1 h
at 4 ◦C: Before cryo-conservation at −80 ◦C, the
RNAlater was removed completely. Cartilage samples
were cryo-pulverized (59012N, Biospec, Bartlesville,
OK) and gently resuspended in TriFast™ (VWR, Ger-
many)mixed with 1-bromo-3-chloropropane (Sigma
Aldrich, MO). Centrifugation was performed after
10 min of incubation for 10 min at 10 000× g. The
top aqueous phase was further used for RNA isola-
tion using the RNeasy Mini Kit (QIAGEN, Germany)
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Table 2. Sequences of primers used for qPCR.













according to the protocols provided. cDNA synthesis
and qPCR were performed as described above.
2.10. Statistical analysis
Statistical analysis was performed with the Graph-
Pad Prism V.8 software. Quantitative data is shown
as mean ± SEM for gene expression data and
mean ± SD for all other data. Since the number
of samples was small and Gaussian distribution was
not assumed, we used the Kruskal-Wallis test with
Dunn’s multiple comparison as non-parametric stat-
istical test for group differences. Each SFCC from one
donor was assumed to be an individual replicate, and
thus paired analysis was not performed. Statistical
numbers and adjusted p-values are listed in supple-
mentary results. A p-value of <0.05 was considered to
be statistically significant. Image analysis was carried
out blinded for treatment groups. Important num-
bers and adjusted p-values are stated either in the text
or in the graphs. Due to the explorative character of
this study, no sample size calculation was performed.
2.11. In silico model generation
To describe the temporal evolution of the spatial
distribution of cellular and matrix-related processes
in the in vitro model of OA, PDEs were used to
interpret the experimental outcomes and to enable
the identification of key steps within the progres-
sion of matrix degradation. The parameters of the
in silico model were calibrated based on the histo-
morphometric in vitro data for distribution of type
II collagen (Col–2) and cell numbers. Since each
section of the SFCCs which were analyzed had a
thickness of 8 µm, we transformed the dimension
from area (mm2) to volume (m3). The geometrical
shape of the SFCCs was approximated by a cylindrical
form (radius r = x = 5.0 · 10−3 m and height
h= y= 4.5 · 10−3 m) (figures 1 and 4A). SFCCs show
a cylinder-like shape comparable to the disc form that
has been described by others before [33, 34]. This
cylinder-like construct was surrounded by culture
medium, so that the added IL–1β was able to diffuse
into the SFCC from all surfaces. The cylindrical form
of the SFCC was radially symmetric around its cen-
ter. Therefore, the computations were performed on
a two-dimensional rectangle instead of the full three-
dimensional domain (figures 1 and 4(A)). In this first
modeling approach, we only focused on the effects of
IL–1β, although the in vitro model was additionally
stimulated with TNFα. Based on the mathematical
model byKar et al (table A2) the adaptedmodel (table
3) was obtained as described in the following. For
equation (1), it was possible to distinguish between
the decrease due to the matrix formation and due to
IL–1β by comparing the reduction of the cell dens-
ity under non-inflammatory and inflammatory con-
ditions in the in vitromodels. Thus, we could identify
the parameters p1 (non-inflammatory conditions)
and p9 (inflammatory conditions) separately. Follow-
ing Kar et al, we expected a small increase of Col–2
under non-inflammatory conditions (small value for
p2) which was negligible compared to the signific-
ant decrease induced by the MMPs [23]. Further-
more, we have omitted equation (3) for degCol–2.
This component cannot be reliably measured and has
no significant impact on other components. MMP
measurements are only used for verification (figure
1), and therefore, parameter p4 and the basal MMP
activity p6—for which no estimates exist, have been
omitted. Finally, in the IL–1β equation (5), the diffu-
sion from outside is certainly the predominant source
of IL–1β, which can also be verified e.g. by per-
forming simulations of the model of Kar et al with
and without a correspondingly simplified equation
for IL–1β.
The generated systems of time-dependent PDEs
were solved using the state-of-the-art software pack-
age KARDOS [35, 36]. Given a user-specified accur-
acy tolerance, the code automatically computes
numerical approximations by means of a fully adapt-
ive grid in space and time based on local error estim-
ates with optimal computational complexity. The
graphical outputs were produced using MATLAB
(Version 2017b, The MathWorks, Inc., Natick, MA).
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Table 3. Reduced mathematical model of in vitromodel resembling onset of OA.
No. Equation Biological reference
(1) ∂Cell
∂t =−p1Cell− p9IL Cell Cell apoptosis stimulated by IL–1β
(2) ∂Col




2MMP+ p5Cell IL Change of MMP–1/–3/–13 due to diffusion and increased
MMP–1/–3/–13 release by IL–1β stimulated cells
(4) ∂IL
∂t = DIL∇
2IL Diffusion of IL–1β
3. Results
3.1. SFCCs show stable cartilage-like phenotype
over 3 weeks
To evaluate the cellular andmatrix composition of the
SFCCs under non-inflammatory conditions, samples
were taken weekly over a period of 3 weeks (d0, 7,
14, 21; n = 3; one sample per donor at each time
point). Alcian blue staining for SFCC sections was
performed at all time points and revealed the con-
stant presence of glycosaminoglycans (GAGs) (figure
2(A)). Hematoxylin & Eosin (H&E) staining showed
heterogeneity of the formed constructs but no obvi-
ous morphological changes in cell and matrix com-
position between time points (figures 2(A) and (B)).
In addition, a layer-like structure was visible that
led to a certain loose morphology as a result of the
embedding procedure. Cell density decreased over
the period of 3 weeks from a mean cell density of
1.378 ± 694 cells mm−2 at d0 to a mean cell dens-
ity of 505 ± 268 cells mm−2 at d21 (figure 2(C)).
Although this difference is not statistically significant,
there is a clear biological relevance that should be con-
sidered. In addition, histomorphometry revealed a
higher cell count in theOuter Area (Ot.A.) than in the
Total Area (Tt.A.), indicating a spatial arrangement of
cells within the construct (figure 2(C)). Type I colla-
gen (Col–1) coverage was higher than type II colla-
gen coverage (Col–2) although no difference could be
identified between time points (figure 2(D)). qPCR
analysis revealed the mRNA expression of the cartil-
age specific markers COL2A1 and ACAN, although
COL1A1 expression was higher when compared to
that of COL2A1 (figure 2(E)). COL10A1 expression
was low in comparison with all other genes. No stat-
istical differences were found between time points
indicating a stable phenotype over time. With respect
to the induction of chondrogenesis, we found a strong
upregulation of COL2A1 at day 0 when compared to
monolayer MSCs (figure A3(A)). In addition, there
is a more pronounced expression of COL2A1 than
COL1A1 or COL10A1 (figure A3(A)). Although sig-
nificant differences do remain when comparing the
results to native human cartilage (figure A3(B)), we
did not observe osteogenic induction/mineralization
(figure A4). Hence, SFCCs revealed a cartilage-like as
evidenced by gene expression and histological ana-
lysis (figure 2).
3.2. Stimulated SFCCs show cellular changes and
matrix degradation
To model the inflammatory environment of OA,
SFCCs were treated with IL–1β and TNFα. Both
are considered to be the most important proinflam-
matory cytokines during the onset of OA. Cytokines
were applied with concentrations of 50 ng ml−1
for IL–1β, and 100 ng ml−1 for TNFα, represent-
ing a highly aggressive proinflammatory stimulation
in order to achieve maximal effects on the SFCCs.
Tissue softening was observed macroscopically by
volume increase of SFCCs stimulated for 3 weeks
(STIM) compared to untreated controls (CTL) which
was partly reversed after 3 additional weeks without
cytokine treatment (REG) (figures 3(A) andA2). This
observationwas supported by histologicalH&E stain-
ing, microscopically indicating pronounced water
retention, maceration of the superficial cell layer and
morphological changes in cell phenotypes in the
STIM group (figure 3(B)). Immunohistological ana-
lysis showed a constant Col–1 coverage with no stat-
istically significant differences between groups (figure
3(C)). Col–2 coverage however decreased after stim-
ulation with IL–1β and TNFα to a mean cover-
age of 14.4 ± 5.5% (STIM) and moreover signi-
ficantly to 8.8 ± 5.9% (REG), when compared to
the untreated controls (25.3 ± 4.7%; figure 3(C)).
Histomorphometry revealed statistically significant
changes between groups in cell count per area for
the Tt.A., Ot.A. and Outer Core Area (Ot.C.A.; figure
3(D)). Therefore, a lower cell density was observed in
the STIM group compared to the CTL, while slight
changes were also seen in the REG group compared
to CTL. No significant differences were found in the
In.C.A. (figure 3(D)). TUNEL staining showed a few
TUNEL positive cells in the CTL group while more
TUNEL positive cells were found in the STIM group
(figure A5).
OnmRNA level,COL1A1was significantly down-
regulated upon cytokine stimulation in comparison
with controls (figure 4(E)). The gene expression of
COL2A1 and ACAN was obviously lower in the
STIM and REG group. Interestingly, COL10A1 was
upregulated in the REG group (figure 3(E)). As
expected, gene expression levels of the inflammatory
markers IL1, IL6 and IL8 were significantly upregu-
lated compared to untreated controls (figure 3(F)).
Gene expression of TNF was not found to be different
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Figure 2. Experimental results after cultivating SFCCs for 3 weeks under non-inflammatory conditions. (A) Exemplary images of
histological staining with hematoxylin & eosin (H&E) in two different magnifications. (B) Exemplary images of Alcian blue
staining, Col–2 and Col–1 immunohistochemistry, scale bars= 200 µm at 100×magnification. (C) Histomorphometry results
for cell count within total area (Tt.A.) and outer area (Ot.A.). X-axes show time points from d0–d21, y-axes show cell count
[cells m−3], bars indicate mean± SD and individual data points. (D) Immunohistochemistry coverage for Col–2 and Col–1.
X-axes show time points from d0–d21, y-axes show relative coverage area in %, bars indicate mean± SD and individual data
points. (E) Gene expression studied via qPCR for COL2A1, COL10A1, ACAN and COL1A1. X-axes show time points from
d0–d21, y-axes show relative mRNA expression normalized to the housekeeper EF1A graph bar with mean± SEM and individual
data points. Statistical differences between groups were tested with the Kruskal-Wallis test and Dunn’s multiple comparisons test
(see also table A3). ns= p > 0.05.
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Figure 3. Experimental results after cultivating SFCCs for 3 weeks under non-inflammatory conditions (CTL), with IL–1β and
TNFα (STIM) or under non-inflammatory conditions for additional 3 weeks after stimulation (REG). (A) Macroscopic overview
on different SFCCs exemplary for each condition. (B) Exemplary images of SFCCs stained with H&E for CTL, STIM and REG
group. Scale bars= 200 µm. Arrows indicate tissue softening and changes of cellular phenotypes. (C) Immunohistochemistry
coverage for Col–2 and Col–1. x-axes show experimental groups, y-axes show relative coverage area in %, bars indicate
mean± SD and individual data points. (D) Histomorphometry results for cell count per area within total area (Tt.A.), outer area
(Ot.A.), outer core area (Ot.C.A.) and inner core area (In.C.A.). X-axes show time points from d0–d21, Y-axes show cell count
[cells m−3], bars indicate mean± SD and individual data points. (E)–(G) Gene expression studied via qPCR. Graph bar show
with mean± SEM and individual data points. Statistical differences between groups were tested with the Kruskal-Wallis test and
Dunn’s multiple comparisons test (see also tables A4 and A5). ns= p > 0.05, ∗p < 0.05, ∗∗p < 0.01.
between the experimental groups. However, IL1, IL6
and IL8 were numerically diminished in the REG
compared to the STIM group although no statistical
significance was detected (figure 3(F)). MMP1 and
9
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MMP3were significantly upregulated in the cytokine-
treated group compared to the CTL group and
numerically downregulated in the REG compared to
the STIM group (figure 3(G)). There were no signific-
ant differences in gene expression forMMP13 within
the experimental groups. In summary, stimulation
with IL–1β andTNFα leads toOA-like changeswhich
can be observed in vivo during the early phase of the
disease. Additional cultivation for 3 weeks without
cytokines after stimulation did partially reverse those
changes.
3.3. Refining an existing mathematical model
result in a reduced PDEmodel of the in vitro
observations
In order to focus on the main processes of cartilage
degradation expected during OA onset, the in silico
model was built on the assumption that under non-
inflammatory conditions, the chondrocytes (termed
here as cells) produce ECM (heremainly Col–2) while
under inflammatory conditions with the addition of
IL–1β, cells release MMPs, which then degrade the
ECM, and potentially go into apoptosis (see figure 1).
Within the mathematical model, we focused on the
specific Col–2 degrading enzymes MMP–1, –3 and –
13. Table 3 shows the underlying equations derived
from the pathway described above and our in vitro
observations (adapted from [23]). Considering the
underlying in vitro experiments and the complexity of
the derived in silico model, it was necessary to derive
a reduced model preserving our in vitro observations
and the underlying biology.
First, we studied the stability of the homogen-
eous nonlinear dynamical system derived from our
reduced order model by neglecting diffusive pro-
cesses. It turned out that all states of equilibrium
are Lyapunov stable, i.e. small perturbations of the
equilibrium points stay small for all times. Next,
applying a sensitivity analysis, we found out that all
parameters exhibit sufficiently large sensitivities with
respect to variations in cell and Col–2 concentrations.
This formed the basis for our parameter calibration
described in the following.
In table 4 the parameter values, initial values and
the boundary conditions to solve the mathematical
(PDE) system are described. Concerning the para-
meter values, the cell apoptosis rate p1 was fitted by a
least squares approach, utilizing measurements of the
cell concentration (n = 3, d = 0, 7, 14, 21). Since the
MMP–1/–3/–13 measurements have been neglected
up to now, the diffusion coefficient is taken from the
literature (MMP–1 [37];). The remaining parameters
have been calibrated with our in vitro observations
using a least squares fitting. For MMP–1/–3/–13,
we assumed that there are homogeneous Neumann
boundary conditions for all surfaces. Because the
evolution of the cell number and Col–2 was described
by ODEs, i.e. where no diffusion is present, there
exist no boundary conditions for these components.
Due to the diffusion of IL–1β into the SFCC with
a constant concentration of IL–1β in the surround-
ing media, inhomogeneous Dirichlet boundary con-
ditions were assumed to be present on the outer sur-
faces. For the inner surface of the construct (center
of the cartilage construct), homogeneous Neumann
boundary conditions were applied ensuring the sym-
metry assumption on the SFCC.
3.4. Modeling the in vitro findings of
cytokine-stimulated SFCCs in silico to resemble
basic processes of cartilage degradation
Since the cells are inhomogeneously, spatially dis-
tributed (figure 2), we determined an initial distri-
bution based on the in vitro observations (figure
A6). Computational results of the in silico model
are shown in figure 4. The model described in table
1 makes it possible to represent the in vitro exper-
iments. Under proinflammatory stimulation with
IL–1β, the cell number decreased over time given the
initial distribution (first row of figure 4(B)), which
matches the in vitro measurements (figure 3(D)).
Col–2 decreased spatiotemporally assuming a homo-
geneous initial distribution (second row in figure
4(B)). Since IL–1β entered from the outside and
stimulated the MMP–1/–3/–13 production, MMPs
increased on the boundaries first and diffused fur-
ther into cartilage (third row in figures 4(B) and (C)).
Under non-inflammatory conditions, the IL–1β con-
centration was assumed to be zero. This also holds
true for MMP–1/–3/–13 (see table 3, equations (3)
and (4)). Thus, Col–2was constant over time and cells
decrease only due to matrix formation leading to a
representation of the healthy state observed in vitro
as well.
To predict cellular and matrix-related changes
over a longer time period (5 weeks) and a
10-fold lower concentration of IL–1β stimulation
(5 ng ml−1) - which is more comparable to the
in vivo situation - we accordingly adapted the in silico
model. We observed a full penetration of IL–1β and
MMP–1/–3/–13, a fast decline in the cell number,
but a rather slower Col–2 degradation when com-
pared to the 3 weeks simulation which had higher
IL–1β concentrations (supplementary video (avail-
able online at stacks.iop.org/BF/12/045016/mmedia)
Appendix A).
3.5. MMP staining in the SFCCs verifies in silico
simulations
In order to verify the mathematical model, MMP–1
and MMP–13 were stained via immunofluorescence
for CTL, STIM and REG sections and analyzed for
their spatial distribution and displayed as a sum of
that. Therefore, MMP coverage normalized to the cell
number was slightly higher in the STIM group (figure
4(D)). The relative MMP coverage was lower in the
inner core area (In.C.A.) than it was in that of the
Ot.C.A. (figures 4(E) and (F)). This also matches the
10
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Figure 4. Results from the in silicomodel. (A) Explanation of the dimensions and axes. (B) Spatial-temporal development of Cell
[1 m−3] (first row), Col–2 [%] (second row), IL–1β [mol m−3] (last row) and (C) MMP–1/–3/–13 [mol m−3] (third row) over
3 weeks. The PDE model described in Table 3 was solved with the adaptive finite element toolbox KARDOS [24, 25] and
MATLAB. (D) MMP–1/–13 were stained in CTL, STIM and REG and normalized to the cell count (total area= Tt.A.). (E)
Quantitative analysis was performed for inner core (In.C.A.) and outer core area (Ot.C.A.) for CTL and STIM are only to be
compared to the results from the in silicomodel. Graphs show box and whiskers plots (Min-Max). (F) Exemplary images for
MMP–1 staining of CTL vs. STIM. The scale bar indicates 200 µm.
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results gained from the in silicomodel and nicely veri-
fies our approach.
4. Discussion
Since multiple approaches and a variety of OA
model systems are necessary to fully understand the
complexity of this disease, we here report on a suc-
cessful combination of in vitro and in silicomodeling
to simulate the main features of OA, matrix degrad-
ation and the upregulation of proinflammatory
cytokines induced by stimulating scaffold-free
cartilage-like constructs with IL–1β and TNFα.
Inmost cases, cartilage explants or monolayer cell
cultures are used as an in vitro model to study OA
and its underlying mechanism or to test potential
therapeutic options. However, there are some stud-
ies using tissue-engineered cartilage for their experi-
ments such as those ofMohanraj et al reported similar
outcomes using tissue-engineered cartilage compared
to cartilage explants in a model of post-traumatic OA
[10, 38] However, most studies on tissue engineered
cartilage still focus on the development of regenerat-
ive approaches for cartilage repair and do not con-
sider using their tissues as in vitro models for the
study of cartilage and OA pathophysiology [12, 14,
15, 39, 40]. SFCCs revealed a cartilage-like phenotype
detected by gene expression and histological analysis
(figure 2); however, significant differences do remain
when comparing the results to native human cartilage
(figure A3(B)). Thus, the gene expression of COL1A1
and the presence of Col–1 on a protein level were still
visible in all SFCCs examined. hMSCs have the poten-
tial to differentiate into different lineages including
the chondrogenic, osteogenic and adipogenic lineage,
although it has not been yet described that MSCs can
fully formhuman articular cartilage in vitro or in vivo.
The major challenges to achieve full phenotypic con-
version are the profound induction of chondrogenesis
as indicated by e.g. upregulated COL2A1 expression
(figure A3(A)) and the maintenance of the chondro-
genic phenotype over a longer time period (figures
2(C)–(E)). The 3D structure of the SFCCs was gained
through biomechanical loading [41, 42]. However, it
is clear that further improvements can be achieved by
e.g. adding transforming growth factor beta (TGFβ)
[13, 15, 41], using culture regimes that are specifically
adapted to the timepoint of chondrogenesis [18, 43]
or using iPSCs as cell source [44, 45]. Of note, we
could not observe hypertrophic cells or mineraliza-
tion which has been described for mesenchymal con-
densation in vitro [16, 46]. By using a macroscale
approach (constructs app. 0.5 cm diameter), we avoid
the disadvantages of pellets regarding their physiolo-
gically irrelevant size, geometry, high cell number
and density compared to the matrix and mechanical
properties [15].
The in vitro simulation of the inflammatory
environment in OA through a cytokine treatment
with IL–1β at 50 ng ml−1 and TNFα at 100 ng ml−1
allowed us to observe significant changes in the
SFCCs with regard to a decrease in cell density and
matrix degradation (figure 3) [47, 48]. Although
the in vivo concentrations for IL–1β and TNFα are
known to be much lower as demonstrated in syn-
ovial fluid of patients suffering from knee OA [49],
cytokine concentrations of 1–100 ngml−1 are usually
applied when mimicking the proinflammatory envir-
onment in early OA in vitro. The latter situation is
necessary in order to shorten the length for treatment
by adapting the in vitro experiments, because the
chronic degenerative joint diseaseOA in humans usu-
ally evolves over decades. IL–1β and TNFα do not
only contribute to the upregulation of proteases but
also inhibit the synthesis of ECM molecules, mainly
Col–2 and aggrecan [50, 51]. MMPs are one pre-
dominant group of enzymatic proteins which plays
an important role in the pathogenesis of OA [3, 52].
In both our in vitro studies and in the in silico
model, we focused onMMP–1,−3, and−13 as main
Col I and II degrading enzymes [53] since MMP–2
(gelatinase A) and MMP–9 (gelatinase B) are known
to interact with Col IV (MMP–2) and are mainly
involved in wound healing (both) or bone develop-
ment (MMP–9) [54–56]. Furthermore, MMP–9 is
induced by MMP–3 and−13 [57].
Mathematical models are very flexible, enabling
adjustments and testing of various hypotheses in par-
allel. However, biological experiments are most often
complex, expensive and resource-demanding, leading
to a gain of less experimental data than model para-
meters can provide [58]. Thus, problems with model
non-identifiability can occur, sincemodel parameters
cannot be estimated properly. Experimental design
approaches aim to resolve these problems by identi-
fying the data gap and proposing the required addi-
tional experimental data. The flexibility of mathem-
atical models including experimental design can be
used to structure future in vitro or in vivo mod-
els efficiently. However, the first considered math-
ematical model, which takes most of the prominent
mechanisms of OA pathogenesis into account, has
unidentifiable parameters (table A2). Its applicability
is nevertheless limited, since neither enough exper-
imental human data nor reliable literature-based
parameters are available for model calibration and
validation. This means that more quantitative meas-
urements of the components at different time and
spatial points are needed. The reduced model, how-
ever, does allow us to reproduce the experimental
data with significantly fewer parameters (table 3).
Validation concerning MMP–1/−13 measurements
which were not used to calibrate the model indic-
ates that the reduced in silico model is suited to
investigate the influence of different targets for mat-
rix degradation (figure 4). In addition, the Supple-
mentary video in this article shows the feasibility of
the in silico model as a prediction tool for further in
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vitro experiments. The observed fast decline in the
cell number accompanied by a slower Col–2 degrad-
ation is in accordance with a previously published
study indicating a high chondrocyte death before
matrix changes occur [59]. In comparison to the
model described by Kar et al [23], our model still
considers changes of the cell concentration in space
as well as over time. A more detailed analysis of the
model proposed by Kar et al revealed IL–1α as the
driving force in the model, while MMP–1/−3/−13,
Col–2 and degraded Col–2 only have a small influ-
ence on the remaining components. Thus, the sim-
plified model in our study displays the same fea-
tures but at the same time involves a smaller number
of parameters and uncertainties. Other mathemat-
ical simulation approaches for OA cartilage degrad-
ation and cartilage focus on e.g. poroelastic mod-
els or coupling cellular phenotype and mechanics
[26, 60, 61].
Nevertheless, there are many ways to foster the
current approach. The proposed in vitro model dis-
plays only one specific part of the disease and includes
only one tissue type, although OA has been described
as a whole organ disease including several tissues
such as the synovial membrane and the subchond-
ral bone. Thus, we are currently working on a more
complex whole joint model for both in vitro and
in silico aspects. Furthermore, biomechanical loading
has not yet been addressed within the first in vitro
and in silico models presented here, although one’s
awareness of its tremendous impact has already been
published [62]. Moreover, we shortened the exper-
imental time window by using high concentrations
of the proinflammatory cytokines IL–1β and TNFα
in our experiments. That bridges the long-lasting
cumulative effect of these cytokines over years and
decades in the course of OA pathogenesis. Finally,
an extension of the in silico model should include
the treatment with TNFα due to its important role
in OA. For a profound model validation and para-
meter fitting, more quantitative in vitro data will
be necessary.
5. Conclusion
In this study, we describe a human 3D in vitro
model based on SFCC (mesenchymal condensa-
tion) which simulates the main features of cartil-
age degradation—inflammation and upregulation of
matrix degrading enzymes. Advantages of such a
model include the 3D environment, the possibil-
ity for mid-throughput analysis, a sufficient sample
volume (macroscale) for several analyses and a
wide availability of tissue-engineered cartilage with
more scaffold-free approaches emerging. With the
combination of in vitro and in silico modeling, we
aim to allow the immediate adaptation and modi-
fications of different models. We strived to develop
a mathematical model to refine and optimize the
in vitro model and vice versa, especially regarding
the development of a whole joint in vitro/in silico
model.
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Figure A1. Pipeline for histomorphometric analysis. (A) Histomorphometric analysis for cell count per area using a modified
color deconvolution method. A 50×magnification overview image of an H&E stained section was taken. The section outline was
defined using the Polygonal Selection tool in ImageJ (1). In order to subtract the background (or gap area) the Color Threshold
tool was utilized (2). Next, the Color Deconvolution plugin (3) was used to obtain the hematoxylin color channel only in which
the cell nuclei could be identified using a threshold for brightness (4). Particle analysis could then be performed based on the
binary image attained in the previous step to obtain the cell count per area [cells mm−2]. (B) For further analysis, the ‘Total Area’
was further divided into an ‘Outer Area’ by scaling the region of interest (ROI) for ‘Total Area’ to 0.95 for X- and Y-axes. The
remaining ‘Core Area’ was then divided into an ‘Outer Core Area’ and an ‘Inner Core Area’ by scaling the ROI for the ‘Core Area’
by 0.5 for the X-and Y-axes.
Figure A2. Comparison of the wet weight after stimulation for 3 weeks. The increase in the wet weight indicates water
retention induced by matrix degradation. Graph bar show with mean± SEM. Statistical differences between groups were
tested with the Kruskal-Wallis test and Dunn’s multiple comparisons test.
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Figure A3. RNA expression of COL1A1, COL2A1 in italic and ACAN in SFCCs compared to undifferentiated monoloayer hMSCs
and native human cartilage. (A) Relative mRNA expression (2−∆∆Ct) normalized to the housekeeper EF1A and MSCs and
COL2/COL1 and COL2/COL10 ratio; (B) Relative mRNA expression (2−∆Ct) normalized to the housekeeper EF1A graph bar
with mean± SEM. For SFCCs all data from d0-21 were grouped together (figure 2(D)). Cartilage was collected from three
different donors from almost unaffected sites (femoral condyles). Statistical differences between groups were tested with the
Mann-Whitney test. ∗∗p < 0.01. Graph bars with mean± SEM and individual data points.
Figure A4. Exemplary von Kossa and Alizarin red staining of SFCCs at day 21 compared to a control which was treated during
SFCC generation with osteogenic induction medium. Scale bars= 200 µm at 100×magnification.
Figure A5. Exemplary TUNEL staining of SFCCs at day 21 comparing CTL and STIM. Scale bars= 200 µm. Positive control was
treated with DNase I prior to staining.
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Figure A6. Initial cell distribution [1 m−3], see figure 4(A) for an explanation of the dimensions and axes.
Table A2. PDE model of the in vitromodel resembling the onset of OA modified from Kar et al [23].
No. Equation Biological reference
(1) ∂Cell
∂t = −p1Cell− p9IL Cell Cell apoptosis stimulated by IL–1β
(1.1) −p1Cell Normal decrease due to ECM formation
(1.2) −p9IL Cell Cell apoptosis due to IL–1β
(2) ∂Col
∂t = p2Cell− p3MMP Col Increase of Col–2 over time depending on
cell concentration and decrease of Col–2 by
MMP-induced degradation
(2.1) +p2Cell Production by cells
(2.2) −p3 MMP Col Degradation by MMPs
(3) ∂ degCol
∂t = DdegCol∇
2 degCol+ p3MMP Col Change of degraded Col–2 due to diffusion,
and its source—degradation of Col–2 caused
by MMPs
(3.1) +DdegCol∇2 degCol Diffusion of degCol–2
(3.2) +p3 MMP Col Production by MMP-based Col–2 degradation
(4) ∂MMP
∂t = DMMP∇
2MMP− p4MMP degCol+ p5Cell IL+ p6 Change of MMP due to diffusion, and its
source—increased MMP release by IL–1β
stimulated cells
(4.1) +DMMP∇2MMP Diffusion of MMP
(4.2) −p4 MMP degCol MMP activity decreases by degradation of
Col–2
(4.3) +p5Cell IL Production by IL–1 β stimulated cells
(4.4) +p6 Basal MMP activity
(5) ∂IL
∂t = DIL∇
2IL− p5Cell IL− p7IL+ p8Cell IL Change of IL–1β due to diffusion, and its
source—increased by stimulated cells
(5.1) +DIL∇2IL Diffusion of IL–1β
(5.2) −p5Cell IL Decrease by IL–1β induced cell apoptosis
(5.3) −p7IL Natural decrease of IL–1β—consumption
(5.4) +p8Cell IL Production by stimulated cells
Cell in 1 m−3 = chondrocytes/differentiated hMSCs; Col= Col–2 volume fraction; degCol= degraded Col–2 volume fraction;
MMP=Matrix-metalloproteinases; IL= Interleukin–1β
Table A3. Results from the Kruskal-Wallis test for figure 2.
Kruskal-Wallis test
Figure 2 Specification H p-value
Cells - Tt.A. 95% 6.39 0.79B
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Table A4. Results from the Kruskal-Wallis test for figure 3.
Kruskal-Wallis test
Figure 3 Specification H p-value
Col–1 2.68 0.27C
Col–2 8.59 0.006
Tt.A. 95% 10.71 0.001
Ot.A. 5% 9.36 0.004
Ot.C.A. 50% 10.33 0.002
D



















Specification Comparison Adjusted p-value
CTL vs. STIM 0.20
STIM vs. REG 0.68
Figure 3(C) Col–2
CTL vs. REG 0.01
CTL vs. STIM 0.005
STIM vs. REG 0.99
Figure 3(D) Tt.A. 95%
CTL vs. REG 0.05
CTL vs. STIM 0.007
STIM vs. REG 0.48
Figure 3(D) Ot.A. 5%
CTL vs. REG 0.30
CTL vs. STIM 0.008
STIM vs. REG 0.99
Figure 3(D) Ot.C.A. 50%
CTL vs. REG 0.03
CTL vs. STIM 0.03
STIM vs. REG 0.41
Figure 3(E) COL1A1
CTL vs. REG 0.89
CTL vs. STIM 0.02
STIM vs. REG 0.54
Figure 3(F) IL1
CTL vs. REG 0.54
CTL vs. STIM 0.02
STIM vs. REG 0.54
Figure 3(F) IL6
CTL vs. REG 0.54
CTL vs. STIM 0.03
STIM vs. REG 0.41
Figure 3(F) IL8
CTL vs. REG 0.89
CTL vs. STIM 0.03
STIM vs. REG 0.41
Figure 3(G)MMP1
CTL vs. REG 0.89
CTL vs. STIM 0.02
STIM vs. REG 0.54
Figure 3(G)MMP3
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